» Articles » PMID: 15173791

Moderate Level Sedation During Endoscopy: a Prospective Study Using Low-dose Propofol, Meperidine/fentanyl, and Midazolam

Overview
Date 2004 Jun 3
PMID 15173791
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Propofol provides several benefits over benzodiazepine and narcotic agents as a sedative medication for endoscopic procedures, including faster recovery and improved patient satisfaction. However, its use generally has been limited to anesthesiologists because of the risks associated with deep sedation.

Methods: One hundred patients undergoing colonoscopy or EGD were sedated with low-dose propofol, midazolam, and fentanyl (or meperidine). Depth of sedation was assessed at 2-minute intervals by an independent observer by using the American Society of Anesthesiologists criteria. Recovery time was determined by using paired neuropsychometric tests. A post-procedure satisfaction survey and 24-hour follow-up questionnaires were administered.

Results: For colonoscopy and EGD, respectively, the mean propofol dose was 98 mg and 79 mg, the mean midazolam dose was 0.9 mg and 0.8 mg, the mean fentanyl dose was 69 mcg and 63 mcg, and the mean meperidine dose was 42 mg (for both procedures). There were 628 assessments of the level of sedation performed during 74 colonoscopies and 101 assessments during 26 EGDs. The level of sedation was minimal in 77%, moderate in 21%, and deep in 2% of assessments. Nine of the 13 episodes of deep sedation were recorded during colonoscopy and 4 during EGD. In no instance was more than a single assessment of deep sedation recorded during one procedure. Ninety-eight percent of patients were satisfied with the sedation, and 71% returned to their usual activities within 2 hours of discharge. There was no serious adverse event.

Conclusions: Endoscopic sedation with low-dose propofol, a narcotic agent, and midazolam produces a moderate level of sedation. The quality of sedation and measures of recovery are comparable with the results reported with standard-dose propofol.

Citing Articles

The Efficacy and Safety Profile of Balanced Propofol Sedation for Bronchoscopy.

Wu X, Zhang L, Zhou Z, Qi L, Liu Y, Du X Ther Clin Risk Manag. 2024; 20:849-860.

PMID: 39691941 PMC: 11649497. DOI: 10.2147/TCRM.S495253.


Transcutaneous Electrical Acupoint Stimulation Combined with Moderate Sedation of Remimazolam Tosilate in Gastrointestinal Endoscopy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Xu J, Tan H, Zhang L, Zhou Z, Yuan L, Kong L Pain Ther. 2024; 13(4):919-936.

PMID: 38890239 PMC: 11254895. DOI: 10.1007/s40122-024-00618-1.


Effect of moderate versus deep sedation on recovery following outpatient gastroscopy in older patients: a randomized controlled trial.

Chen B, Lu L, Zhai J, Hua Z Surg Endosc. 2023; 38(3):1273-1282.

PMID: 38102399 DOI: 10.1007/s00464-023-10642-5.


Effect of intravenous lidocaine on outcomes in patients receiving propofol for gastrointestinal endoscopic procedures: an updated systematic review and meta-analysis.

Wu F, Zhan L, Xu W, Bian J Eur J Clin Pharmacol. 2023; 80(1):39-52.

PMID: 37962581 DOI: 10.1007/s00228-023-03589-y.


Simulation-Based Gastrointestinal Endoscopy Sedations: A Novel Validation to Multidrug Pharmacodynamic Modeling.

Liou J, Wang H, Kuo I, Chang W, Ting C Pharmaceutics. 2022; 14(10).

PMID: 36297491 PMC: 9610933. DOI: 10.3390/pharmaceutics14102056.